
AAV6 Rep-Cap plasmid (serotype 6-specific AAV RC6 plasmids)


AAV serotype 6 (AAV capsid 6) system - Introduction
GeneMedi's AAV6 Rep-Cap plasmid (serotype 6-specific AAV RC plasmid), also named AAV6-RC plasmid, or AAV-RC6 plasmid, is part of AAV6 packaging system. AAV6 Rep-Cap plamid supplies the AAV6 Rep (replication) proteins and the AAV6 capsid protein.
You can produce AAV6 paticle in 293T cell line in high titer using GeneMedi's AAV6 Rep-Cap plasmid with GeneMedi's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV6 vector has been validated in neuron (CNS), lung, liver, heart and muscle, with potential applications in tissue-specific gene therapy.
AAV6 has also been proved a high transduction efficency in T cell, wtih potential applications in T cell-mediated cancer immunotherapies, including Chimaeric antigen receptor T(CAR-T) and TCR engineered T (TCR-T) cell therapy.
You can produce AAV6 paticle in 293T cell line in high titer using GeneMedi's AAV6 Rep-Cap plasmid with GeneMedi's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV6 vector has been validated in neuron (CNS), lung, liver, heart and muscle, with potential applications in tissue-specific gene therapy.
AAV6 has also been proved a high transduction efficency in T cell, wtih potential applications in T cell-mediated cancer immunotherapies, including Chimaeric antigen receptor T(CAR-T) and TCR engineered T (TCR-T) cell therapy.
Product Name | Organization Type | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
AAV6 Rep-Cap Plasmid Cat.No.:P-RC08 Serotype: AAV6 Size: 5ug |
Academic | 935 | ||
AAV6 Rep-Cap Plasmid Cat.No.:P-RC08 Serotype: AAV6 Size: 5ug |
Industry R&D (excluding CRO&CDMO&CXO) |
Inquiry | ||
AAV6 Rep-Cap Plasmid Cat.No.:P-RC08 Serotype: AAV6 Size: 5ug |
CRO&CDMO& CXO&CMC& Manufacturing company |
Inquiry | ||
Shipping Cost: | 169.00 | |||
Total: | ||||
AAV6 vector tissue tropism and gene transduction (serotype-specific AAV infection)
The tissue tropism of AAV6 vector has been validated in neuron (CNS), lung, liver, heart and muscle, with potential applications in tissue-specific gene therapy.AAV6 has also been proved a high transduction efficency in T cell, wtih potential applications in T cell-mediated cancer immunotherapies, including Chimaeric antigen receptor T(CAR-T) and TCR engineered T (TCR-T) cell therapy.

Figure. Selected transduction results of AAV in vitro (in 293T cell line)
Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml
Cells: HEK-293T
MOI: MOI=1×104
Determine assay: 36 hours post infection, immunofluorescence microscopyOther AAV Rep-Cap Plasmid